-
Mashup Score: 0Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axis - BMC Medicine - 1 year(s) ago
Background Oxaliplatin resistance is a complex process and has been one of the most disadvantageous factors and indeed a confrontation in the procedure of colorectal cancer. Recently, long non-coding RNAs (lncRNAs) have emerged as novel molecules for the treatment of chemoresistance, but the specific molecular mechanisms mediated by them are poorly understood. Methods The lncRNAs associated with…
Source: BioMed CentralCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Frontline Zolbetuximab Plus CAPOX Meets PFS, OS End Points in Claudin 18.2+ Gastric or GEJ Cancers - 1 year(s) ago
The addition of zolbetuximab to capecitabine and oxaliplatin resulted in a statistically significant improvement in progression-free survival and overall survival vs placebo/CAPOX in patients with Claudin 18.2–positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal cancers, meeting the primary and secondary end points of the phase 3 GLOW trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Zolbetuximab + #capecitabine and #oxaliplatin resulted in a statistically significant improvement in PFS and OS vs placebo/CAPOX in pts w/ Claudin 18.2–positive, HER2-, locally advanced unresectable or metastatic gastric or GEJ cancers. #stomachcancer https://t.co/AKpXcMf94R https://t.co/mbqMA1xXTV
-
-
Mashup Score: 0Frontline Zolbetuximab Plus CAPOX Meets PFS, OS End Points in Claudin 18.2+ Gastric or GEJ Cancers - 1 year(s) ago
The addition of zolbetuximab to capecitabine and oxaliplatin resulted in a statistically significant improvement in progression-free survival and overall survival vs placebo/CAPOX in patients with Claudin 18.2–positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal cancers, meeting the primary and secondary end points of the phase 3 GLOW trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Zolbetuximab + #capecitabine and #oxaliplatin resulted in a statistically significant improvement in PFS and OS vs placebo/CAPOX in pts w/ Claudin 18.2–positive, HER2-, locally advanced unresectable or metastatic gastric or GEJ cancers. #stomachcancer https://t.co/qIcYf31ul9
-
-
Mashup Score: 1VOCAL CORD PARALYSIS INDUCED BY OXALIPLATIN: DIFFERENCIAL DIAGNOSIS OF HYPERSENSITIVITY - 1 year(s) ago
Article InfoPublication HistoryAccepted: November 6, 2022Received in revised form: October 31, 2022Received: August 4, 2022Publication stageIn Press Journal Pre-ProofFootnotesAuthor #1. A Barra-CastroAlicia Barra-Castroe-mail address: [email protected]Medical Doctor ( MD)Author #2. MP Berges-GimenoMaria Pilar…
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Press! #VOCAL #CORD #PARALYSIS INDUCED BY #OXALIPLATIN: DIFFERENCIAL DIAGNOSIS OF #HYPERSENSITIVITY https://t.co/k8HbBSC310
-
-
Mashup Score: 14
Background Peritoneal metastasis (PM) remains a major obstacle in the treatment of stage IV gastric cancer. This is a dose-escalation study of intraperitoneal (IP) paclitaxel combined with intravenous (IV) fluorouracil, leucovorin, and oxaliplatin (FOLFOX) to determine the recommended phase II dose in gastric cancer patients. Methods Patients with gastric adenocarcinoma and PM were enrolled. The…
Source: SpringerLinkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Safety and Efficacy of Intraperitoneal #Paclitaxel Plus Intravenous #Fluorouracil , #Leucovorin , and #Oxaliplatin ( #FOLFOX ) for #GastricCancer with Peritoneal Metastasis https://t.co/wxznWPs19w #VisualAbstract @McMastersKelly https://t.co/QnTvaOHoHG
-
-
Mashup Score: 0
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A Phase I Trial of Oxaliplatin, Irinotecan, and S‐1 Combination Therapy (OX‐IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403) #PancreaticCancer #CombinationTherapy #Oxaliplatin #Irinotecan https://t.co/thZkHQwHcM https://t.co/il3DkRMxqw
-
-
Mashup Score: 2Apatinib, S-1 plus oxaliplatin treats locally advanced gastric cancer effectively, safely - 3 year(s) ago
In the treatment of locally advanced gastric cancer, apatinib combined with S-1 plus oxaliplatin was a safe and effective neoadjuvant treatment, according to a nonrandomized controlled study. “Neoadjuvant chemotherapy could decrease the tumor stage, increase the R0 resection rate and provide survival benefits for patients with advanced GC,” Jian-Xian Lin, MD, PhD, Fujian Medical
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI: In the treatment of locally advanced #gastriccancer, #apatinib combined with S-1 plus #oxaliplatin was a safe and effective neoadjuvant treatment @JAMANetworkOpen #GITwitter #MedTwitter https://t.co/1BCpEVLKI9
-
-
Mashup Score: 4Apatinib, S-1 plus oxaliplatin treats locally advanced gastric cancer effectively, safely - 3 year(s) ago
In the treatment of locally advanced gastric cancer, apatinib combined with S-1 plus oxaliplatin was a safe and effective neoadjuvant treatment, according to a nonrandomized controlled study. “Neoadjuvant chemotherapy could decrease the tumor stage, increase the R0 resection rate and provide survival benefits for patients with advanced GC,” Jian-Xian Lin, MD, PhD, Fujian Medical
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Apatinib, S-1 plus #oxaliplatin treats locally advanced #gastriccancer effectively, safely @JAMANetworkOpen #GITwitter #MedTwitter https://t.co/1BCpEVLKI9
-
-
Mashup Score: 0Dr. Eng on the Role of Preventive Screening in CRC - 3 year(s) ago
Cathy Eng, MD, FACP, FASCO, discusses the role of preventive screening in colorectal cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@CathyEngMD, of @VUMC_Cancer, discusses contraindications for oxaliplatin-based therapy in colorectal cancer #crc #oxaliplatin https://t.co/ejgFxqpVaO
-
-
Mashup Score: 0Dr. Eng on the Role of Preventive Screening in CRC - 3 year(s) ago
Cathy Eng, MD, FACP, FASCO, discusses the role of preventive screening in colorectal cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@CathyEngMD, of @VUMC_Cancer, discusses contraindications for oxaliplatin-based therapy in colorectal cancer #crc #oxaliplatin https://t.co/ejgFxqpVaO https://t.co/I1AvBJd4GJ
-
Translational study from Zhijian Zheng et al finds that long non-coding RNA AC092894.1 promotes #oxaliplatin resistance in #ColorectalCancer https://t.co/xaoife90sg https://t.co/mtF9kR5mTn